The number of approved Ultomiris administered was 101 until April.

Ultomiris, a treatment for paroxysmal nocturnal hemoglobinuria (PNH), has been shown to have completely replaced Soliris, the existing treatment since its benefits in June last year.

Both are expensive rare drugs, and must be approved in advance by the Board of Review and Assessment before administration. According to the HIRA on the 8th, a total of 101 cases of Ultomiris were approved in advance by April for PNH patients after their benefits in June.

Soliris did not have any prior approval applications for PNH patients at this time. Ultomiris has completely replaced Soliris, at least for new patients. Th